What Aciloc-RD Treats: Main Uses and Benefits

---

The primary therapeutic role of Aciloc-RD is to offer symptomatic support for symptoms related to heightened physiological activity and symptoms related to organ-specific functional stress. The medicine is relevant in contexts involving heightened systemic burden, applied across therapeutic areas where additional symptomatic support is needed.

The combination is commonly used across conditions presenting with systemic or localized discomfort, relevant in conditions characterized by periods of heightened symptoms such as Gastroesophageal Reflux Disease (GERD) and Functional Dyspepsia, and conditions involving inflammatory or irritative processes such as Peptic Ulcer Disease. It is applied in situations involving certain distressing symptoms, including heartburn, acid regurgitation, nausea, and bloating. The medicine may assist with managing symptom clusters that become more disruptive during flare-ups, offering symptomatic relief that helps patients cope more steadily with difficult episodes.

---

Quick Fact: Support for Combined Symptoms
Symptom Focus: Nausea, vomiting, heartburn, and postprandial fullness (symptoms related to physical discomfort).
Benefit: Assists with maintaining functional stability.
Clinical Use: Applied in scenarios where additional management of discomfort is required.

Regulatory References

1. Health Canada InfoWatch on Domperidone

The eligibility for Aciloc-RD, a Fixed-Dose Combination of Ranitidine and Domperidone, is determined by strict rules set forth in regulatory documents, primarily focusing on cardiac and organ health.

Populations Contraindicated (Must Not Use)

Official labeling strictly prohibits use in patients with:

• Cardiac Risks: Known prolongation of the QTc interval, significant electrolyte disturbances (e.g., hypokalemia), or pre-existing underlying cardiac diseases (e.g., congestive heart failure).
• Liver Function: Moderate or severe hepatic impairment (liver disease).
• Gastrointestinal Risk: Conditions where stimulating gut motility is harmful, such as gastrointestinal hemorrhage, obstruction, or perforation.
• Other: Hypersensitivity to the components or a prolactin-releasing pituitary tumor (prolactinoma).

Age-Related and Conditional Use

Population Group	Eligibility Status
Children (Under 12 years)	Use is not established and not recommended.
Adolescents (12 years and older, ≥35 kg)	Eligible under standard conditions.
Older Adults (Geriatric)	Use requires caution due to increased cardiac risk.
Severe Renal Impairment	Restricted use; dosing frequency must be reduced.
Pregnancy/Lactation	Not recommended unless the therapeutic benefit is deemed necessary, as components are excreted into breast milk.

These official rules define the specific patient populations for whom the medicine is prohibited or restricted by regulatory authorities.

Interactions with other medicines and products

This section outlines the officially documented interaction patterns for the Ranitidine/Domperidone fixed-dose combination, based strictly on regulatory sources.

Contraindicated and Restricted Combinations

Co-administration with Potent CYP3A4 Inhibitors (e.g., systemic Azole Antifungals like Ketoconazole, Macrolide Antibiotics like Erythromycin) is contraindicated. This restriction is due to the potential for a significant increase in Domperidone plasma concentration.

Medicines formally classified as QTc-prolonging agents (e.g., certain Antiarrhythmics, Antipsychotics) are also contraindicated. This prohibition exists due to a documented additive pharmacodynamic risk of serious ventricular arrhythmia.

Interaction Type	Interacting Substance Examples
Metabolic (CYP3A4)	Potent/Moderate CYP3A4 Inhibitors, Grapefruit Juice
Pharmacodynamic	QTc Prolonging Medicines, Anticholinergic Drugs
Absorption Alteration	Antacids, Certain Azole Antifungals, Erlotinib

Exposure and Timing Constraints

The Ranitidine component increases gastric pH, which can reduce the absorption of co-administered drugs that require an acidic environment (e.g., certain antifungals). Conversely, Ranitidine has been documented to increase the exposure (AUC) of drugs such as Triazolam.

Antacids and other acid-suppressing agents must not be taken simultaneously with Domperidone, requiring a timing separation to maintain adequate bioavailability. Interaction risk with CYP3A4 inhibitors is noted to be higher in patients older than 60 years and those with severe renal impairment, requiring special consideration as documented in regulatory information.

How Aciloc-RD Works

Aciloc-RD is a fixed-dose combination product that modulates gastric acidity through two distinct pharmacodynamic mechanisms. The Proton Pump Inhibitor ( PPI) component, Rabeprazole, is activated in the acidic environment of the secretory canaliculi within gastric parietal cells. The activated metabolite covalently and irreversibly binds to the H^+/ K^+- ATPase (Proton Pump), which is the enzyme responsible for the terminal step of Hydrochloric Acid ( HCl) secretion. This inhibition reduces the overall volume of acid secreted into the gastric lumen.

The H2-receptor antagonist component, Ranitidine, exerts its action by competitively binding to Histamine H2 receptors located on the basolateral membrane of the parietal cell. This antagonism mitigates Histamine-mediated signal transduction, which reduces Proton Pump activation. The dual interaction—direct H^+/ K^+- ATPase inhibition and competitive H2 receptor antagonism—sustains an elevated gastric pH by simultaneously inhibiting basal and stimulated HCl secretion.

The administration of Aciloc-RD (a fixed-dose combination of Ranitidine and Domperidone) is governed by established dosage restrictions, primarily those related to the Domperidone component. These guidelines define the maximum dose, frequency, and duration of use.

---

Official Administration Guidelines

Property	Instructional Detail
Route of Administration	The medicine is approved for the oral route as an oral tablet.
Dosing Schedule	The maximum Domperidone component dose is 10 mg per intake. The maximum daily dose is 30 mg.
Frequency and Timing	The tablet is taken up to three times per day (TID). It is recommended to take the medicine before meals (pre-prandial).
Course Duration	Use should be limited to the shortest possible duration, and must not normally exceed one week (seven days).
Age/Weight Rules	Oral solid forms are generally for patients 12 years of age or older weighing 35 kg or more.
Renal Adjustment	The dosing frequency should be reduced (to once or twice daily) in patients with severe renal impairment.
Missed Dose Rule	If a dose is missed, it must be omitted, and the patient should take the next scheduled dose at the usual time; do not double the dose.

---

Use Protocol Structure

The official instructions establish a precise, time-constrained protocol for administering this medication. This protocol defines the maximum daily limit, mandates pre-meal timing, and limits the overall course of use to a maximum of one week. These constraints ensure adherence to the standardized regimen.

Aciloc-RD is a combination medication containing Rabeprazole and Domperidone. Rabeprazole belongs to the class of proton pump inhibitors (PPIs), and Domperidone is a prokinetic agent. The combination is typically investigated for the management of gastroesophageal reflux disease (GERD), functional dyspepsia, and conditions associated with delayed gastric emptying.

Research Evidence / Overview of Studies

Phase 3 Clinical Trials

Research utilized a randomized, double-blind, placebo-controlled design and investigated potential changes in the long-term prognosis for the target condition.

• Primary Endpoint: The main goal of the research was to assess changes in symptom scores over a 12-week period. One study assessed the time to observed effect.
• Duration: The studies varied in duration, ranging from 6 months to 2 years, with some open-label extensions.
• Results Overview: Research explored the compound’s effects. The results demonstrated varied effects on the primary and secondary endpoints across different patient subsets. The combination therapy was evaluated for differences in pain scores compared with placebo.
• Safety Profile: Long-term studies assessed the safety profile of the compound. Adverse events observed were generally categorized as mild to moderate. Studies noted specific considerations for participants with existing kidney conditions.

Post-Marketing Surveillance and Long-Term Data

The compound has been monitored through post-marketing surveillance programs to gather post-authorization data beyond the controlled environment of clinical trials.

• Real-World Application: Research investigated this approach to understand how the compound's profile translates to diverse patient populations in non-trial settings.
• Complications: Further research is needed to determine whether the compound affects the risk of complications over time.

Key Studies & References Expert opinion on the prescription practice of a combination of rabeprazole and domperidone for managing nighttime heartburn in GERD

Common questions about Aciloc-RD (FAQ)

---

Q: What is the main difference between Aciloc-RD and a regular antacid?

The Ranitidine component of Aciloc-RD and a regular antacid work using different mechanisms. Antacids primarily work by neutralizing the stomach acid that is already present in the stomach at the time of use. The Ranitidine component, which is an H2-receptor antagonist, works by blocking specific receptors to actively reduce the amount of new acid the stomach produces over a period of time.

---

Q: Does Aciloc-RD help with general indigestion or is it only for specific conditions?

Official product information indicates the combination is used to manage a range of acid-related digestive disorders. This includes common symptoms of indigestion (dyspepsia), as well as specific conditions such as Gastroesophageal Reflux Disease (GERD) and peptic ulcers. The medicine is designed to target both acid and movement problems in the upper gut.

---

Q: How quickly should a person generally expect Aciloc-RD to start working?

According to official sources, the Domperidone component is rapidly absorbed, with its peak concentration in the blood typically occurring in about one hour. Relief from the Ranitidine component's acid-reducing effects can also generally be expected to begin around 60 minutes after taking the dose.

---

Q: Is it true that Aciloc-RD can be taken without food?

Official guidance generally recommends taking the medicine before meals (pre-prandial). This timing is advised to support the intended absorption and effects, particularly for the Domperidone component. Administration should be strictly guided by the specific instructions provided by a healthcare professional.

---

Q: Is Aciloc-RD the same type of drug as other 'prazole' medicines?

Aciloc-RD is a fixed-dose combination of two different drug classes: a H2-receptor antagonist (Ranitidine) and a prokinetic agent (Domperidone). This is distinct from the 'prazole' family of medicines, such as Omeprazole, which belong to the Proton Pump Inhibitor (PPI) class.

---

Q: Do regulatory bodies list any specific dietary restrictions while taking Aciloc-RD?

Official guidance warns that avoiding certain items, such as alcohol, may reduce the risk of irritation and side effects. Other common medical information often suggests limiting foods like citrus fruits or soft drinks that can irritate the stomach lining.

---

Q: Is Aciloc-RD often associated with feelings of dizziness or lightheadedness?

Dizziness and feelings of sleepiness or drowsiness are listed among the commonly reported adverse reactions associated with this combination. Official safety information notes that caution is advised regarding activities that require concentration due to these effects.

---

Q: Can Aciloc-RD be stopped suddenly, or is a gradual approach described?

Official regulatory guidance emphasizes that treatment should be limited to the shortest possible duration, often not exceeding one week. For such a short-term course, there are typically no detailed instructions in official documentation regarding a gradual cessation or tapering process.

---

Q: What type of stomach problems is Aciloc-RD specifically licensed to treat?

Official documentation states the medicine is licensed to treat a range of conditions involving both excess acid and motility issues. This includes Gastroesophageal Reflux Disease (GERD), peptic ulcer disease in the stomach and upper intestine, and general symptoms of indigestion.

---

Q: What are the common reasons a doctor might prescribe Aciloc-RD instead of a single-ingredient drug?

This combination is often prescribed to offer a dual-action approach that targets multiple issues simultaneously. The formulation manages acid production (Ranitidine) and also helps with gastric emptying and motility (Domperidone). This combined strategy is useful for patients whose symptoms involve both acid excess and digestive movement problems.

---

Q: Are there any known issues with taking Aciloc-RD with common pain relievers?

Official drug interaction studies indicate that H2 antagonists like Ranitidine may alter the absorption or clearance of some Non-Steroidal Anti-Inflammatory Drugs (NSAIDs). Any potential interaction depends on the specific pain reliever, and such matters are typically verified with a healthcare provider.

---

Q: Can Aciloc-RD affect the absorption of vitamins or other supplements?

Official safety and warnings information suggests that the acid-reducing component may interfere with the body’s ability to absorb certain nutrients. Specifically, the Ranitidine component may affect the absorption of Vitamin B12 (cobalamin), especially during long-term treatment, as this process requires stomach acid.

---

Q: How long does the effect of a single dose of Aciloc-RD typically last?

The duration of symptom relief provided by the Ranitidine component is generally documented to last between 4 to 10 hours after administration. The Domperidone component has an elimination half-life of approximately 7 to 9 hours in healthy individuals.

---

Q: Is it necessary to avoid alcohol completely while using Aciloc-RD?

Regulatory documentation advises patients to avoid alcohol consumption while taking the medicine. This is because alcohol can increase the risk of side effects like drowsiness and may also irritate the stomach, potentially worsening the underlying condition being treated.

How to Store and Dispose of Aciloc-RD

The proper storage and disposal of Aciloc-RD (Omeprazole and Domperidone combination) ensures its effectiveness and safety, as outlined in official regulatory documents.

Official Storage Requirements

Requirement	Details
Temperature	Store at room temperature, typically below 25°C or 30°C. Do not freeze or refrigerate.
Protection	Keep in the original container or blister pack, protecting it from both light and moisture.
Handling	Keep the medicine out of the sight and reach of children.

Disposal Instructions

Do not dispose of unused or expired Aciloc-RD in household trash or by flushing it down a toilet or sink. Dispose of the medication according to the official local regulations or return it to a pharmacy or drug take-back program for proper pharmaceutical waste management.